Navigation Links
Scripps Research scientists identify new class of antimalarial compounds
Date:11/17/2011

LA JOLLA, CA November 17, 2011 - A international team led by scientists from the Genomics Institute of the Novartis Research Foundation (GNF) and The Scripps Research Institute has discovered a family of chemical compounds that could lead to a new generation of antimalarial drugs capable of not only alleviating symptoms but also preventing the deadly disease.

In a study published November 17, 2011, in Science Express, the advance online publication of the journal Science, Elizabeth Winzeler, PhD, a Scripps Research associate professor and member of the GNF, and colleagues demonstrated that the class of compounds was more effective against malaria than some commercially available drugs.

Most antimalarial drugs are only effective during the blood stage, and those that do work in the liver have notable side effects. However, the new class of compounds identified by the team is highly effective against the parasite in both the blood and the liver.

"Because the parasite blood stages are more amenable to high-throughput screening, much research has focused on that area," said Stephan Meister, PhD, a research associate in the Winzeler lab and first author of the new paper. "We're excited to have found a class of compounds that appears to target a novel gene and is highly active against the liver stage parasites in mice. This compound class provided us with a lead for the development of novel anti-malaria drugs."

A Complicated Lifecycle

Despite long-standing efforts to control malaria globally, the disease remains endemic in many parts of the world. According to the World Health Organization, malaria affected about 225 million people in 2009, and killed nearly 800,000. The disease, which tends to strike the poorest and most vulnerable populations in Asia, Africa, and the Americas, is caused by Plasmodium parasites transmitted through the bites of infected mosquitoes.

The Plasmodium parasite has a complicated lifecycle in two hostsmosquitoes and humans (or other vertebrate). When a malaria-infected mosquito feeds on a person, the parasite enters the human body. Within 30 minutes, the parasite has infected liver cells, where it develops for about eight days without causing noticeable symptoms. In some cases it can even go into hiding in the liver and persist for several months to years.

When this period is over, however, the parasite (now in a different form) leaves the liver and enters red blood cells, where it grows and multiplies. When the infected red blood cells eventually burst, the parasite and Plasmodium toxins are released into the bloodstream, and the person feels sick. Symptoms include fever, chills, headache, and other flulike symptoms; in severe cases, patients can experience convulsions, coma, and liver and kidney failure, which can be fatal.

If a mosquito bites the infected person at this point, the parasite will enter the mosquito, where it will continue the cycle by maturing into a form that can infect the next human host.

Mining the Data

To find compounds to act against the parasite in more than one stage of its lifecycle, the team screened thousands of candidates that were already known to act against malaria parasites in the blood. Only 15 percent looked as if they might also work in the livera strong indication, Winzeler said, that "a lot of compounds that are active against blood stages probably aren't going to do anything about eliminating malaria."

The group then identified the strongest candidates for drug development by mining the data for groups of related compounds that all showed activity in the liver. In the end, they settled on a cluster related to the chemical imidazolopiperazine. "When we analyzed all of the data, we saw that multiple members of this imidazolopiperazine family were active in blood and liver stages," Winzeler said.

The imidazolopiperazine family of compounds was especially attractive because it was chemically unrelated to existing antimalarial drugs, and therefore less likely to run into problems with existing resistance. "I wouldn't want to base a multimillion dollar clinical trial on compounds for which there may be pre-existing resistance," said Winzeler. "Ultimately, we want to have something that will still be effective in 10 years."

The group used an automated system of their own design to see how these new compounds fared against malaria parasites incubated in liver cells in the lab. An imaging apparatus took multiple images of each collection of cells over time, and a computer script analyzed those images to see how well the various compounds inhibited the growth of the parasites.

In the end, the team was able to develop compounds that could be taken orally and would stay in the blood long enough to be a viable candidate for drug development. When it was given to mice, the compound provided complete protection against the parasite in the liver, and worked better in the blood than some commercially available drugs.

Spurring Drug Discovery

To better understand how the compound works, the team exposed successive generations of infected mosquitoes to low levels of the compound to produce resistant strains of parasites. They then sequenced the parasites' whole genomes and looked for genetic changes. "Every [resistant] strain we looked at had a mutation in the same gene," she said.

By offering a target for other new antimalarial drugs that can act in both the liver and the blood, that gene will provide other researchers fresh ammunition in the fight to eradicate the disease. So, too, will the decision by the team to make all of their data available online.

"We have been making all of our data available to the community to spur drug development," Winzeler said. "The data on all of the compounds that were tested will eventually be released, and this will allow people at universities and research institutes around the world to mine this data, and to use it to guide their own drug discovery efforts."


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Research scientist receives $1 million research grant from Novo Nordisk
2. Scripps Florida scientist awarded $2.2 million grant to study hepatitis C
3. Scripps research scientist wins $3.6 million NIH Method to Extend Research in Time award to study alcoholism in Native Americans
4. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
5. Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer
6. Scripps Research scientists define cellular pathway essential to removing damaged mitochondria
7. Scripps Translational Science Institute joins Jackson Laboratory tumor consortium
8. Scripps Research scientists show how shifts in temperature prime immune response
9. CIRM awards Scripps Research Institute scientists $3.5 million
10. Scripps Research wins more than $2 million to study prostate cancer
11. New lupus drug results from Scripps Research technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research scientists identify new class of antimalarial compounds
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: